🔴 Telix Pharmaceuticals extends recent weakness amid ongoing regulatory concerns and broader market sentiment

Telix Pharmaceuticals is trading at $10.51 (4.2% down) in after-hours trading, extending recent weakness.

• Shares remain under pressure due to the continuing overhang from past FDA Complete Response Letters regarding candidates like TLX250-CDx and an SEC subpoena, both disclosed in 2025.
• No new company-specific catalyst was identified for today's price movement, which appears consistent with softer healthcare-sector sentiment.
• Recent reports indicate a slight decrease in short interest for the company.